mixed aspergillus injection, solution
alk-abello, inc. - aspergillus flavus var. oryzae (unii: q6z8uk5r3g) (aspergillus flavus var. oryzae - unii:q6z8uk5r3g), aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), aspergillus repens (unii: sq89e6lome) (aspergillus repens - unii:sq89e6lome), aspergillus terreus (unii: qbn8k7055x) (aspergillus terreus - unii:qbn8k7055x) - aspergillus flavus var. oryzae 0.05 g in 1 ml - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater
aspergillus- aspergillus niger var. niger liquid
uspharmaco - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6) - aspergillus niger var. niger 4 [hp_x] in 10 ml - for temporary relief of external urogenital soreness / itching
aspergillus- aspergillus niger var. niger suppository
bioresource inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6) - aspergillus niger var. niger 3 [hp_x] - for treatment of lymphatic stagnation.
mixed aspergillus- aspergillus niger, aspergillus repens, aspergillus oryzae, aspergillus terreus injection, solution mixed fea
alk-abello, inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), aspergillus repens (unii: sq89e6lome) (aspergillus repens - unii:sq89e6lome), aspergillus flavus var. oryzae (unii: q6z8uk5r3g) (aspergillus flavus var. oryzae - unii:q6z8uk5r3g), aspergillus terreus (unii: qbn8k7055x) (aspergillus terreus - unii:qbn8k7055x) - fraxinus americana pollen 0.05 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse
voriconazole wockhardt voriconazole 200 mg powder for injection vial
wockhardt bio pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sodium chloride; hydroxypropylbetadex - voriconazole wockhardt is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
voriwok voriconazole 200 mg powder for injection vial
wockhardt bio pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sodium chloride; hydroxypropylbetadex - voriwok is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
voriconazole interpharma voriconazole 200 mg powder for injection vial
arrotex pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - solution, powder for - excipient ingredients: hydroxypropylbetadex; hydrochloric acid; sodium chloride - voriconazole is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp. and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.
mixed aspergillus- aspergillus flavus var. oryzae, aspergillus niger var. niger, aspergillus repens, aspergillus terreus injecti
alk-abello, inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), aspergillus repens (unii: sq89e6lome) (aspergillus repens - unii:sq89e6lome), aspergillus flavus var. oryzae (unii: q6z8uk5r3g) (aspergillus flavus var. oryzae - unii:q6z8uk5r3g), aspergillus terreus (unii: qbn8k7055x) (aspergillus terreus - unii:qbn8k7055x) - gibberella zeae 20000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse
allergen pack aspergillus fumigatus solution
alvix laboratories, llc - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - aspergillus fumigatus 20000 [pnu] in 1 ml
multi-system support aspergillus niger cladosporium candida albicans thyroidinum ustilago maidis aconitum nap. antimonium tart.
newton laboratories, inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6) - aspergillus niger var. niger 15 [hp_x] in 1 g